Biopharmaceutical Industry Activity Accelerates
The biopharmaceutical sector is experiencing significant activity, with major acquisitions focusing on RNA therapies and rare diseases.
Key players, including BioCryst and Bristol Myers Squibb, are leading the charge in this industry shift.
- Bristol Myers Squibb
- BioCryst Pharmaceuticals
- AstraZeneca
- Novo Nordisk
BioCryst Pharmaceuticals has announced a definitive agreement to acquire Astria Therapeutics for an implied value of $13 per share, representing an enterprise value of up to $700 million.
The acquisition received unanimous approval from both the BioCryst and Astria boards of directors.
Author's summary: Biopharmaceutical industry sees major acquisitions.
More News
- Rugby tournament fosters next generation of leaders
- Is Economics Promoting Inequality?
- Win up to £1,000 at the British Rowing Indoor Championships 5K EXR Invitational - British Rowing
- PAL Named 2nd Best Airline in SEA, Announces $315M Upgrade Plan
- Founding KISS guitarist Ace Frehley dies, aged 74
- Labour’s dual mandate led to higher inflation | Kiwiblog
- A Missile Past Its Prime: Why the Minuteman III’s Endless Life Extension Forces a Rethink of America’s Nuclear Triad
- Democrats say Trump needs to be involved in shutdown talks. He’s shown little interest in doing so
- Bolton, 76, indicted under US Espionage Act, faces 180 years in prison - Lynnwood Times
- Nigeria records first month-on-month food deflation in over 13 years